Discovery and Development of VX-950, a Novel, Covalent, and Reversible Inhibitor of Hepatitis C Virus NS3.4A Serine Protease

Publisher： Bentham Science Publishers

E-ISSN： 2212-3989|6|1|3-16

ISSN： 1871-5265

Source： Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol.6, Iss.1, 2006-03, pp. : 3-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The investigational hepatitis C virus (HCV) protease inhibitor telaprevir [VX 950] appears to be effective and well tolerated

By  

Inpharma, Vol. 1, Iss. 1569, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Novel tripeptide inhibitors of hepatitis C virus NS3 serine protease

By  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 2, 2003-02 ,pp. : 267-272

Informa Healthcare

Access to resources Recommend Favorite

Advances in the Development of Macrocyclic Inhibitors of Hepatitis C Virus NS3-4A Protease

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 14, 2010-10 ,pp. : 1403-1422

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Development of Hepatitis C Virus Inhibitors Targeting the NS5A Protein

By  

Mini Reviews in Medicinal Chemistry, Vol. 15, Iss. 7, 2015-06 ,pp. : 553-581

Bentham Science Publishers

Access to resources Recommend Favorite

ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

By  

Current Medicinal Chemistry, Vol. 21, Iss. 28, 2014-09 ,pp. : 3261-3270

Bentham Science Publishers

Access to resources Recommend Favorite